Therapeutic drug monitoring of itraconazole and the relevance of pharmacokinetic interactions

Clinical Microbiology and Infection

Volumn 12, Issue SUPPL. 7, 2006, Pages 97-106

  Dominguez Gil Hurle A ^a   Sanchez Navarro A ^a   Garcia Sanchez M J ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Drug interactions; Itraconazole; Therapeutic drug monitoring

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN B; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; CARBAMAZEPINE; CASPOFUNGIN; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOCHROME P450; ERYTHROMYCIN; FLUCONAZOLE; GLYCOPEPTIDE; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; NIFEDIPINE; PHENYTOIN; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; RITONAVIR; UNINDEXED DRUG; VINCRISTINE; VORICONAZOLE;

ANTIBIOTIC THERAPY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG SOLUBILITY; FIRST PASS EFFECT; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 33751066478     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01611.x     Document Type: Review

References (61)

1. Testa B, Waterbeemd HV, Folkers G, Gue R, eds. Pharmacokinetic optimization in drug research. Biological, physicochemical, and computational strategies. Zurich: Wiley-VCH, 2001.
2. Thorburn CE, Molesworth SJ, Sutherland R, Tittenhouse S. Postantibiotic and post-β-lactamase inhibitor effects of amoxicillin plus clavulanate. Antimicrob Agents Chemother 1996; 40: 2796-2801.
3. Ambrose PG, Owens RC, Grasela D. Antimicrobial pharmacodynamics. Med Clin North Am 2000; 84: 1431-1436.
4. Firsov AA, Vostrov SN, Lubenko Y, Drlica K, Portonoy YA, Zinner SH. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 1604-1613.
5. Wong-Beringer A, Kriengkauykiat J. Systemic antifungal therapy: New options, new challenges. Pharmacotherapy 2003; 23: 1441-1462.
6. Ensom MHH, Davis GA, Cropp CD et al. Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes? Clin Pharmacokinet 1998; 34: 265-279.
7. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 26: 2211-2221.
8. Poirier JM, Berlioz F, Isnard F et al. Marked intra- and inter-patient variability of itraconazole steady state plasma concentrations. Therapie 1996; 51: 163-167.
9. Hansten PD. Understanding drug-drug interactions. Sci Am Sci Med 1998; 5: 15-25.
10. Preskorn SH. Reducing the risk of drug-drug interactions: A goal of rational drug development. J Clin Psychiatry 1996; 57 (suppl 1): 3-6.
11. Lin JH, Lu AYH. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998; 35: 361-390.
12. Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: Prediction of in vivo activity in humans. J Phamacokinet Biop 1996; 24: 475-490.
13. Preskorn SH, Magnus RD. Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: In vitro and in vivo findings and their implications for patient care. Psychopharmacol Bull 1994; 30: 251-259.
14. Watkins PB, Turgeon DK, Saenger P et al. Comparison of urinary 6-b-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 1992; 52: 265-273.
15. Lown KS, Thummel KE, Benedict PE. The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 1995; 57: 16-24.
16. Cheng CL, Smith DE, Cox SR et al. Correlation between ERMBT and oral exposure to delavirdine mesylate in HIV-positive patients. Pharm Res 1995; 12: S374.
17. Tateishi T, Graham SG, Krivoruk Y, Wood AJ. Omeprazole does not affect measured CYP3A4 activity using the erythromycin breath test (letter). Br J Clin Pharmacol 1995; 40: 411-412.
18. Maertens J, Boogaerts M. The place for itraconazole in treatment. J Antimicrob Chemother 2005; 56 (suppl S1): I33-i38.
19. Willems L, van der Geest R, de Beule K. Itraconazole oral solution and intravenous formulations: A review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther 2001; 26: 159-169.
20. Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 2005; 56 (suppl S1): I17-i22.
21. Hardin TC, Graybill JR, Fetchick R, Woestenborghs R, Rinaldi M, Kuhn JG. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1998; 32: 1310-1313.
22. Koks H, Meenhorst PL, Bult A et al. Itraconazole solution: Summary of pharmacokinetic features and review of activity in the treatment of fluconazole-resistant oral candidosis in HIV-infected persons. Pharmacol Res 2002; 46: 195-201.
23. Mohr JF, Finkel KW, Rex JH, Rodríguez JR, Leitz GJ, Ostrosky-Zeichner L. Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients. Antimicrob Agents Chemother 2004; 48: 3151-3153.
24. Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomised trial. Ann Intern Med 2003; 138: 705-713.
25. Lohitnavy M, Lohitnavy O, Thangkeattiyanon O, Srichai W. Reduced oral itraconazole bioavailability by antacid suspension. J Clin Pharm Ther 2005; 30: 201-206.
26. de Beule K, Van Gestel J. Farmacología de itraconazol. Drugs 2001; 61 (suppl 1): 29-40.
27. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-420.
28. Uekama K. Cyclodextrins in drug delivery system. Adv Drug Deliv Rev 1999; 36: 1-2.
29. Stella VJ, Rao VM, Zannou EA, Zia V. Mechanisms of drug release from cyclodextrin complexes. Adv Drug Deliv Rev 1999; 36 (1): 3-16.
30. Stevens DA. Itraconazole in cyclodextrin solution. Pharmacotherapy 1999; 19: 603-611.
31. Saag M. Itraconazole oral solution: Pharmacokinetics and absorption. AIDS Patient Care STDS 1997; 11 (suppl 1): S16-S17.
32. Van de Velde VJS, Van Peer AP, Heykants JJP et al. Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Pharmacotherapy 1996; 16: 424-428.
33. Heykants J, Van Peer A, Van de Velde V et.al. The clinical pharmacokinetics of itraconazole: An overview. Mycoses 1989; 32: 67-88.
34. Conte JE, Golden JA, Kipps J, McIver M, Zurlinden E. Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. Antimicrob Agents Chemother 2004; 48: 3823-3827.
35. Grant SM, Clissold SP. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989; 37: 310-344.
36. Boelaert J, Schurgers M, Mathys E et al. Itraconazole pharmacokinetics in patients with renal dysfunction. Antimicrob Agents Chemother 1998; 32: 1595-1597.
37. Rajewski RA, Traijer G, Bresnahan J, Jaberaboansari P, Stella VJ, Thompson DO. Preliminary safety evaluation of parenterally administered sulfoalkyl ether beta-cyclodextrin derivatives. J Pharm Sci 1995; 84: 927-932.
38. Girois SB, Chapuis F, Decullier E, Revol BGP. Adverse effects of antifungal therapies in invasive fungal infections: Review and meta-analysis. Eur J Clin Microbiol Infect Dis 2005; 24: 119-130.
39. Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Disp 2004; 32: 1121-1131.
40. Wilke RA, Moore JH, Burmester JK. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genom 2005; 15: 415-421.
41. Potter M. Strategies for managing systemic fungal infection and the place of itraconazole. J Antimicrob Chemother 2005; 56 (suppl 1): 49-54.
42. Yu DT, Peterson JF, Seger DL, Gerth WC, Bates DW. Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions. Pharmacoepide Miol Drug Saf 2005; 14: 755-777.
43. Florea NR, Capitano B, Nightingale CH, Hull D, Leitz GJ, Nicolau DP. Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. Transplant Proc 2003; 35: 2873-7287.
44. Molden E, Garcia BH, Braathen P, Eggen AE. Co-prescription of cytochrome P450 2D6/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies. Eur J Clin Pharmacol 2005; 61: 119-125.
45. Sádaba B, Campanero MA, Quetglas EG, Azanza JR. Clinical relevance of sirolimus drug interactions in transplant patients. Transplant Proc 2004; 36: 3226-3228.
46. Rosenbaum SE, Baheti G, Trull AK, Akhlaghi F. Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. Ther Drug Monit 2005; 27: 116-122.
47. Bermúdez M, Fuster JL, Llinares E, Galera A, González C. Itraconazole-related increased vincristine neurotoxicity. J Pediatr Hematol Oncol 2005; 27: 389-392.
48. Marr KA, Leisening W, Crippa F et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103: 1557-1559.
49. de Jonge ME, Huitema ADR, van Dam SM, Rodenhuis S, Beijnen J. Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes. Anti-Cancer Drug 2005; 16: 331-336.
50. Jia Woei Wong, Ur-Rahman Nisar, Kah Hay Yuen. Liquid chromatographic method for the determination of plasma itraconazole and its hydroxy metabolite in pharmacokinetic/bioavailability studies. J Chromatogr B 2003; 798: 355-360.
51. Craig WA. Pharmacodynamics of antimicrobials: General concepts and applications. In: Nightingale CH, Murakawa T, Ambrose PG, eds. Antimicrobial pharmacodynamics in theory and clinical practice. New York: Marcel Dekker Inc., 2002; 1-23.
52. Van Cutsem J. The in-vitro antifungal spectrum of itraconazole. Mycoses 1989; 32 (suppl 1): 7-13.
53. Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 1998; 42: 3018-3021.
54. Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation 2002; 74: 688-695.
55. Glasmacher A, Hahn C, Leutner C et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999; 42: 443-451.
56. Boogaerts M, Winston DJ, Bjow EJ et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001; 135: 412-422.
57. Berenguer J, Ali NM, Allende MC et al. Itraconazole for experimental pulmonary aspergillosis: Comparison with amphotericin B, interaction with cyclosporine A, and correlation between therapeutic response and itraconazole concentrations in plasma. Antimicrob Agents Chemother 1994; 38: 1303-1308.
58. Glasmacher A, Prentice A, Gorschluter M et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: Evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003; 21: 4615-4626.
59. Poirier JM, Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet 1998; 35: 461-473.
60. Buchkowsky SS, Partovi N, Ensom MH. Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit 2005; 27: 322-333.
61. Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother 2002; 46: 160-165.